This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Oric Pharmaceuticals, Inc.. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Chudi Ndubaku: Innovator in Cancer Treatment
Introduction
Chudi Ndubaku is a notable inventor based in Montreal, Canada, recognized for his contributions to the field of cancer treatment. With a focus on developing innovative pharmaceutical compounds, he has made significant strides in the medical research community.
Latest Patents
Chudi Ndubaku holds two patents, both centered around Polo Like Kinase 4 (PLK4) inhibitors. These patents disclose compounds of Formula (I), or pharmaceutically acceptable salts thereof, that act as inhibitors of PLK4. The patents also detail pharmaceutical compositions that include these compounds along with one or more pharmaceutically acceptable excipients. Furthermore, they outline methods for treating cancer in subjects in need, which involve administering an effective amount of the compounds.
Career Highlights
Chudi Ndubaku is currently associated with Oric Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against cancer, showcasing his commitment to improving patient outcomes through innovative therapies.
Collaborations
Chudi collaborates with Jae Hyuk Chang, contributing to a dynamic research environment that fosters innovation and discovery in the pharmaceutical field.
Conclusion
Chudi Ndubaku's work in developing PLK4 inhibitors represents a significant advancement in cancer treatment. His patents and ongoing research efforts highlight his dedication to improving healthcare through innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile